Geisinger launches ‘MyCode-Connect’: a new era of precision health integrating real-world data and multi-omics
DANVILLE, PA — Geisinger, a leading integrated health system, today announced the launch of MyCode-Connect, a major new program designed to connect multi-omic research directly to clinical breakthroughs and personalized patient care. This initiative represents a significant expansion of Geisinger’s genomic efforts, moving beyond traditional biobanking to seamlessly translate research breakthroughs to routine patient care.
MyCode-Connect is the clinical evolution of MyCode, Geisinger’s pioneering biobanking program. MyCode, with over 370,000 participants to date, has been collecting and conducting research on participant biospecimens, including serial samples over time, since 2007. While MyCode focused on the vital work of collecting and analyzing genomic and health record data, MyCode-Connect will activate that data to transform how diseases are predicted, diagnosed, and treated.
By leveraging years of longitudinal EHR data alongside newly generated multi-omic profiles, we will be able to discover new ways to predict disease risks and tailor treatments with unprecedented accuracy, thereby improving outcomes and reducing costs for patients. A key differentiator of MyCode-Connect is its capacity to provide an expanded view of human biology beyond static genomics into dynamic multi-omics. While DNA provides the blueprint, multi-omics – including proteomics, transcriptomics, and metabolomics – measure what is happening in the body in real time.
“We are moving beyond the era of ‘one-size-fits-all’ medicine,” said Christa L. Martin, PhD, FACMG, chief scientific officer at Geisinger. “By combining our extensive longitudinal EHR data with new multi-omic insights, including DNA sequencing and proteomics, we are giving our clinicians the tools to deliver truly personalized care.”
A strategic platform for biopharma innovation
Beyond its direct clinical impact, MyCode-Connect will also support biopharma partnerships to accelerate the development of next-generation therapies through:
• Precision cohorts: Identifying and stratifying disease populations based on phenotypic and multi-omic signatures.
• Target discovery: Uncovering novel drug targets by correlating multi-omic shifts with 20 years of clinical outcomes.
• Drug repurposing: Revealing new indications by mining decades of data to identify protective therapeutic signals.
• Natural history studies: Mapping the clinical and molecular evolution of disease before and after diagnosis.
• Trial optimization: Improving trial efficiency and success by leveraging multi-omics and EHR data.
• Study recruitment: Recontacting participants for enrollment in clinical trials and other follow-up studies.
MyCode-Connect partnership engagements are structured to respect all existing collaboration and consent obligations.
“Because we have been collecting serial samples through MyCode since 2007 and EHR data since 1996, we possess a biological ‘time machine’,” said Kyle Retterer, chief data science officer at Geisinger. “We can now look back at a patient’s molecular profile from nearly 20 years ago and trace the exact biological shifts that led to their current health status. This isn't just data; it’s a roadmap that allows our biopharma partners to identify drug targets and our clinicians to potentially intervene years earlier than was previously possible.”
About Geisinger College of Health Sciences
Educating. Inspiring. Leading. At Geisinger College of Health Sciences, we bring innovation and purpose together to educate the next generation of healthcare leaders. As the academic and research arm of the Geisinger family, our college was founded to enhance and improve community health, with a focus on discovery, hands-on learning and applied practice across our system. Today, we offer a research institute, graduate medical education, schools of medicine, graduate education and nursing, and faculty and professional development programs. Visit geisinger.edu/gchs.
The College is committed to nondiscrimination in all employment and educational programs or activities. Concerns or questions may be directed to the Title IX coordinator whose contact information is available at geisinger.edu/titleix.
